Skyrizi vs. Ilumya

Reviewed on 12/21/2020

Are Skyrizi and Ilumya the Same Thing?

Skyrizi (risankizumab-rzaa) and Ilumya (tildrakizumab-asmn) injection are interleukin-23 antagonists used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Side effects of Skyrizi and Ilumya that are similar include upper respiratory infections and injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth, hives).

Side effects of Skyrizi that are different from Ilumya include headache, fatigue, and tinea infections (such as ringworm, athlete's foot, and jock itch).

Side effects of Ilumya that are different from Skyrizi include diarrhea.

Both Skyrizi and Ilumya may interact with "live" vaccines.

What Are Possible Side Effects of Skyrizi?

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

What Are Possible Side Effects of Ilumya?

Common side effects of Ilumya include

  • upper respiratory infections,
  • injection site reactions (hives, itching, pain, redness, inflammation, swelling, bruising, hematoma, and bleeding), and
  • diarrhea

SLIDESHOW

Types of Psoriasis: Medical Pictures and Treatments See Slideshow

What Is Skyrizi?

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

What Is Ilumya?

Ilumya (tildrakizumab-asmn) injection is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

What Drugs Interact With Skyrizi?

Skyrizi may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Skyrizi is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Skyrizi and for 4 weeks following completion of therapy. It is unknown if Skyrizi passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Skyrizi, and for 6 days after the last dose.

What Drugs Interact With Ilumya?

Ilumya may interact with live vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Ilumya; it is unknown how it would affect a fetus. It is unknown if Ilumya passes into breast milk. Consult your doctor before breastfeeding.

How Should Skyrizi be Taken?

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

How Should Ilumya be Taken?

The recommended dose of Ilumya is 100 mg at Weeks 0, 4, and every twelve weeks thereafter.

QUESTION

Psoriasis causes the top layer of skin cells to become inflamed and grow too quickly and flake off. See Answer
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
AbbVie Inc. Skyrizi Product Information.

https://www.skyrizi.com

Abbvie. Ilumya Product Information.

www.humira.com/

Health Solutions From Our Sponsors